Rydapt
Author: Rachael Lloyd
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Rydapt is a multiple kinase inhibitor that interferes with cellular signal transduction pathways. While the drug exhibits efficacy against a number of kinases, its efficacy against FLT3 is of particular relevance to AML (Fathi and Chen, 2011). Patients with FLT3-mutated AML represent a key population subtype, and mutations in FLT3, specifically the FLT3- internal tandem duplication (ITD) mutation, can lead to poorer disease prognosis than in patients with wild-type FLT3.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Rydapt : Acute myeloid leukemia (AML)
LIST OF FIGURES
8 Figure 1: Datamonitor Healthcare’s drug assessment summary of Rydapt for acute myeloid leukemia
9 Figure 2: Datamonitor Healthcare’s drug assessment summary of Rydapt for acute myeloid leukemia
LIST OF TABLES
5 Table 1: Rydapt drug profile
7 Table 2: Rydapt pivotal trial data in acute myeloid leukemia
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
IDHIFA 
Sign up to the